284 related articles for article (PubMed ID: 26419509)
1. Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.
Palma BD; Guasco D; Pedrazzoni M; Bolzoni M; Accardi F; Costa F; Sammarelli G; Craviotto L; De Filippo M; Ruffini L; Omedè P; Ria R; Aversa F; Giuliani N
Leukemia; 2016 Feb; 30(2):409-16. PubMed ID: 26419509
[TBL] [Abstract][Full Text] [Related]
2. CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.
Giuliani N; Lisignoli G; Colla S; Lazzaretti M; Storti P; Mancini C; Bonomini S; Manferdini C; Codeluppi K; Facchini A; Rizzoli V
Cancer Res; 2008 Aug; 68(16):6840-50. PubMed ID: 18703490
[TBL] [Abstract][Full Text] [Related]
3. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.
Tian E; Zhan F; Walker R; Rasmussen E; Ma Y; Barlogie B; Shaughnessy JD
N Engl J Med; 2003 Dec; 349(26):2483-94. PubMed ID: 14695408
[TBL] [Abstract][Full Text] [Related]
4. Young female patients with multiple myeloma have low occurrence of osteolytic lesion.
Zhang D; Huang J; Zhang W; Pan L; Zhang D; Zhao P; Wang F; Luo H; He J; Qin Y; Qu Y; Guo T; Niu T; Zheng Y
Bone; 2018 May; 110():21-28. PubMed ID: 29414597
[TBL] [Abstract][Full Text] [Related]
5. Multiple Myeloma: Molecular Imaging with 11C-Methionine PET/CT--Initial Experience.
Dankerl A; Liebisch P; Glatting G; Friesen C; Blumstein NM; Kocot D; Wendl C; Bunjes D; Reske SN
Radiology; 2007 Feb; 242(2):498-508. PubMed ID: 17179397
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease.
Zamagni E; Nanni C; Gay F; Pezzi A; Patriarca F; Bellò M; Rambaldi I; Tacchetti P; Hillengass J; Gamberi B; Pantani L; Magarotto V; Versari A; Offidani M; Zannetti B; Carobolante F; Balma M; Musto P; Rensi M; Mancuso K; Dimitrakopoulou-Strauss A; Chauviè S; Rocchi S; Fard N; Marzocchi G; Storto G; Ghedini P; Palumbo A; Fanti S; Cavo M
Leukemia; 2016 Feb; 30(2):417-22. PubMed ID: 26490489
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spinal bone marrow infiltration in untreated patients with multiple myeloma.
Hur J; Yoon CS; Ryu YH; Yun MJ; Suh JS
Acta Radiol; 2008 May; 49(4):427-35. PubMed ID: 18415787
[TBL] [Abstract][Full Text] [Related]
8. Skeletal imaging and management of bone disease.
Roodman GD
Hematology Am Soc Hematol Educ Program; 2008; ():313-9. PubMed ID: 19074102
[TBL] [Abstract][Full Text] [Related]
9. Update on the pathogenesis of osteolysis in multiple myeloma patients.
Giuliani N; Colla S; Rizzoli V
Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
[TBL] [Abstract][Full Text] [Related]
10. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
Oyajobi BO; Mundy GR
Cancer; 2003 Feb; 97(3 Suppl):813-7. PubMed ID: 12548580
[TBL] [Abstract][Full Text] [Related]
11. Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis.
Haaber J; Abildgaard N; Knudsen LM; Dahl IM; Lodahl M; Thomassen M; Kerndrup GB; Rasmussen T
Br J Haematol; 2008 Jan; 140(1):25-35. PubMed ID: 18005268
[TBL] [Abstract][Full Text] [Related]
12. [Bone disease in multiple myeloma and its mechanism].
Abe M
Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of artificial intelligence-supported assessment of bone marrow infiltration using dual-energy computed tomography in patients with evidence of monoclonal protein - a retrospective observational study.
Fervers P; Fervers F; Kottlors J; Lohneis P; Pollman-Schweckhorst P; Zaytoun H; Rinneburger M; Maintz D; Große Hokamp N
Eur Radiol; 2022 May; 32(5):2901-2911. PubMed ID: 34921619
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow expression of CCL3 is not correlated with the extent of lytic bone lesions.
Cohen Y; Gutwein O; Garach-Jehoshua O; Bar-Haim A; Kornberg A
Acta Haematol; 2014; 132(2):129-33. PubMed ID: 24556596
[No Abstract] [Full Text] [Related]
15. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
[TBL] [Abstract][Full Text] [Related]
16. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma.
Ailawadhi S; Abdelhalim AN; Derby L; Mashtare TL; Miller KC; Wilding GE; Alberico RA; Gottlieb R; Klippenstein DL; Lee K; Chanan-Khan AA
Cancer; 2010 Jan; 116(1):84-92. PubMed ID: 19862816
[TBL] [Abstract][Full Text] [Related]
17. Can whole-body low-dose multidetector CT exclude the presence of myeloma bone disease in patients with monoclonal gammopathy of undetermined significance (MGUS)?
Spira D; Weisel K; Brodoefel H; Schulze M; Kaufmann S; Horger M
Acad Radiol; 2012 Jan; 19(1):89-94. PubMed ID: 22142681
[TBL] [Abstract][Full Text] [Related]
18. Homing characteristics of donor T cells after experimental allogeneic bone marrow transplantation and posttransplantation therapy for multiple myeloma.
van der Voort R; Volman TJ; Verweij V; Linssen PC; Maas F; Hebeda KM; Dolstra H
Biol Blood Marrow Transplant; 2013 Mar; 19(3):378-86. PubMed ID: 23266741
[TBL] [Abstract][Full Text] [Related]
19. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
[TBL] [Abstract][Full Text] [Related]
20. Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma.
Li Y; Zheng Y; Li T; Wang Q; Qian J; Lu Y; Zhang M; Bi E; Yang M; Reu F; Yi Q; Cai Z
Oncotarget; 2015 Sep; 6(27):24218-29. PubMed ID: 26155942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
